Pfizer and Astellas' XTANDI® Approved... - Advanced Prostate...
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Interesting, just sent this to my MO.
Not what you're looking for?
You may also like...
Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage...
Addition of an ARSI to standard ADT significantly increases the risk of fractures and falls in men with prostate cancer
Jones C, Gray S, Brown M, et al. Risk of fractures and falls in men with advanced or metastatic...
Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer: some options
Interesting perspective, but we need more weapons still!...
Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
“the research suggests a differential impact between androgen receptor antagonists (like...
Pluvicto and prostate cancer in the bone (spine)
I have heard the Pluvicto is not the best solution for cancer in the bone due to red blood cell...
Related Posts
- 64Cu-SAR-bisPSMA Is Safe and Highly Effective in Detecting Tumours in Prostate Cancer Patients: results from COBRA trial
Prostate Cancer (stage IV) identified in January and Small Cell Carcinoma (Neuro endocrine) in liver in August. Any suggestions?
Anti-Androgen Therapy and Bone Tumors in Prostate Cancer
Need an Advise and Info on Very Experienced Doctors and Centers to do Proton Treatment of the Prostate in Oligometastatic Setting
Xtandi can fuel spread of bone tumours in advanced prostate cancer?
